ProQR Therapeutics N.V. announced that John Maraganore has joined ProQR as a strategic advisor. Dr. John Maraganore served as the founding CEO and a Director of Alnylam from 2002 to 2021. He continues to serve on the Alnylam Scientific Advisory Board. Prior to Alnylam, he served as an officer and a member of the management team for Millennium Pharmaceuticals Inc.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.92 USD | -1.03% | -3.03% | -3.03% |
May. 09 | Transcript : ProQR Therapeutics N.V. - Special Call | |
May. 09 | ProQR Therapeutics N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.03% | 157M | |
+9.58% | 115B | |
+12.41% | 107B | |
-3.26% | 21.6B | |
-12.38% | 22.31B | |
-5.71% | 19.19B | |
-3.35% | 18.23B | |
-38.57% | 17.62B | |
+7.51% | 14.26B | |
+35.67% | 12.37B |
- Stock Market
- Equities
- PRQR Stock
- News ProQR Therapeutics N.V.
- ProQR Therapeutics N.V. Appoints John Maraganore as Strategic Advisor to the Supervisory Board